Dear Lou,
I have been invested in ATCT since 2005. They had lots of problems which appear to have been cleaned up.
This company is changing its name to Ocata Therapeutics after the Nov. 12, 2014, general meeting.
I believe they will shortly list on the Nasdaq. I think this company may one day be like Apple.
Ken
Hey Ken,
Thanks for the assignment. Advanced Cell Technology Inc. (ACTC) is in clinical trials of its regenerative treatment for Stargardt's macular degeneration, dry age related macular degeneration, and myoptic macular degeneration. Regenerative medicine involves replacing or regenerating human cells, tissues, and even organs. In the fact sheet posted on the company's web site they refer to retinal pigment epithelium cells derived from embryonic stem cells. The company is conducting preclinical research in the treatment of other ocular conditions as well as applications in autoimmune, and inflammatory therapies.
The best outcome for you as a long-term investor would be the listing of the shares on Nasdaq. The OTC Market is seen as a high risk market with limited reporting requirements that would keep many potential investors on the sidelines. I would also advise that if you have been long since 2005 that you should amend your expectations. ACTC traded at substantially higher levels nine years ago and a return to those levels would have, in my opinion, a low probability.
An examination of the charts will provide further research for you to add to the file for ACTC.
The three-year chart depicts a range-bound pattern with support at $6.00 and resistance at $9.00. There was the September spike in 2014 through $9.00 which wasn't sustained as a breakout. The MACD and the RSI both signalled a buy in mid-August and sell at the early September spike high near $13.00.
The six-month chart provides a close up of the buy and sell signals generated by the momentum indicators. There are no patterns at this time to suggest a move higher is in the cards. As a long-term investor trapped in stock that has given up a substantial amount of value you have to ask yourself, when its time to tap out? Capital preservation is not an option; its a requirement of effective asset management.
From the research conducted on your behalf ACTC is in the early stages of the clinical trials process. The conclusion of the trials is still further down the road, suggesting that your nine year vigil has longer to go.
Make it a profitable day and happy capitalism!
Have your own question for Lou? Send it in to lou@happycapitalism.com.